Nicousamide blocks the effects of advanced glycation end products on renal cells

European Journal of Pharmacology

Volumn 674, Issue 2-3, 2012, Pages 455-459

  Li, Hongyan ^a,b   Zhang, Yi ^a   Wang, Hongbo ^a   Zheng, Xuguang ^a   Chen, Xiaoguang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

AGE (Advanced glycation end products); CTGF (Connective tissue growth factor); MMPs (Matrix metalloproteinase); Nicousamide; TGF 1 (Transforming growth factor 1)

Indexed keywords

ADENINE; ADVANCED GLYCATION END PRODUCT; CONNECTIVE TISSUE GROWTH FACTOR; COUMARIN DERIVATIVE; CYTOSINE; GUANOSINE; MATRIX METALLOPROTEINASE; NICOUSAMIDE; THYMINE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; KIDNEY CELL; KIDNEY TUBULE EPITHELIUM; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

ANILINE COMPOUNDS; ANIMALS; CELL LINE, TUMOR; CONNECTIVE TISSUE GROWTH FACTOR; COUMARINS; EPITHELIAL CELLS; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY; KIDNEY TUBULES; MATRIX METALLOPROTEINASES; MESANGIAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84855536205     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.06.056     Document Type: Article

References (44)

1. Ahmed, N., Thornalley, P.J., 2007. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab. 9, 233-245. (Pubitemid 46502041)
2. Ban, C.R., Twigg, S.M., 2008. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers Vasc. Health Risk Manag. 4, 575-596. (Pubitemid 352037917)
3. Barnett, A., 2006. Prevention of loss of renal function over time in patients with diabetic nephropathy. Am. J. Med. 119 (5 Suppl. 1), S40-S47.
4. Berrou, J., Tostivint, I., Verrecchia, F., Berthier, C., Boulanger, E., Mauviel, A., Marti, H.P., Wautier, M.P., Wautier, J.L., Rondeau, E., Hertig, A., 2009. Advanced glycation end products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells. Int. J. Mol. Med. 23, 513-520.
5. Bohlender, J.M., Franke, S., Stein, G., Wolf, G., 2005. Advanced glycation end products and the kidney. Am. J. Physiol. Renal. Physiol. 289, F645-F659. (Pubitemid 41324185)
6. Chen, Y., Blom, I.E., Sa, S., Goldschmeding, R., Abraham, D.J., Leask, A., 2002. CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int. 62, 1149-1159.
7. Forbes, J.M., Cooper, M.E., Oldfield, M.D., Thomas, M.C., 2003. Role of advanced glycation end products in diabetic nephropathy. J. Am. Soc. Nephrol. 14 (Suppl. 30), S254-S258. (Pubitemid 36903936)
8. Forbes, J.M., Fukami, K., Cooper, M.E., 2007. Diabetic nephropathy: where hemodynamics meets metabolism. Exp. Clin. Endocrinol. Diabetes 115, 69-84. (Pubitemid 46408113)
9. Gilbert, R.E., Cox, A., Wu, L.L., Allen, T.J., Hulthen, U.L., Jerums, G., Cooper, M.E., 1998. Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 47, 414-422. (Pubitemid 28104204)
10. Goh, S.Y., Cooper, M.E., 2008. The role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 93, 1143-1152. (Pubitemid 351519698)
11. Gross, J.L., Azevedo, M.J., Silveiro, S.P., Canani, L.H., Caramori, M.L., Zelmanovitz, T., 2005. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28, 176-188.
12. Happer, P.A., Robinson, J.M., Hoover, R.L., Wright, T.C., Karnovsky, M.J., 1984. Improved methods for culturing rat glomerular cells. Kidney Int. 26, 875-880. (Pubitemid 15197010)
13. Ikeda, K., Higashi, T., Sano, H., Jinnouchi, Y., Yoshida, M., Tomohiro Araki, T., Ueda, S., Horiuchi, S., 1996. Nε-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 1996 (35), 8075-8083.
14. Ishimura, E., Sterzel, R.B., Budde, K., Kashgarian, M., 1989. Formation of extracellular matrix by cultured rat mesangial cells. Am. J. Pathol. 134, 843-855. (Pubitemid 19111251)
15. Jafarmejad, A., Bathaie, S.Z., Nakhjavani, M., Hassan, M., 2008. Investigation of the mechanisms involved in the high-dose and long-term acetyl salicylic acid therapy of type I diabetic rats. J. Pharmacol. Exp. Ther. 324, 850-857. (Pubitemid 351185846)
16. Jakus, V., Rietbrock, N., 2004. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol. Res. 53, 131-142. (Pubitemid 38525116)
17. Kaname, S., Uchida, S., Ogata, E., Kurokawa, K., 1992. Autocrine secretion of TGF-β in cultured rat mesangial cells. Kidney Int. 42, 1319-1324.
18. Li, H., Nakamura, S., Morita, T., Suzuki, M., Pischetsrieder, M., Niwa, T., 2006. N2- carboxyethyl-2′-deoxyguanosine, a DNA glycation marker, in kidneys and aortas of diabetic and uremic patients. Kidney Int. 69, 388-392. (Pubitemid 43323092)
19. Li, H., Zheng, X., Wang, H., Zhang, Y., Xin, H., Chen, X., 2010. XL-III-43, a novel coumarin-aspirin compound, prevents diabetic nephropathy in rats via inhibiting advanced glycation end products. Eur. J. Pharmacol. 627, 340-347.
20. McLennan, S.V., Wang, X.Y., Moreno, V., Yue, D.K., Twigg, S.M., 2004. Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology 145, 5646-5655. (Pubitemid 39564606)
21. Miyata, T., Ueda, Y., Asahi, K., Izuhara, Y., Inagi, R., Saito, A., Strihou, C.V.Y.D., Kurokawa, K., 2000. Mechanism of the inhibitory effect of OPB-9195 [(6)-2-Isopropylidenehydrazono- 4-oxo-thiazolidin-5-ylacetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J. Am. Soc. Nephrol. 11, 1719-1725.
22. Murphy, G., Crabbe, T., 1995. Gelatinases A and B. Methods Enzymol. 248, 470-484.
23. Nakamura, S., Li, H., Adijiang, A., Pischetsrieder, M., Niwa, T., 2007. Pyridoxal phosphate prevents progression of diabetic nephropathy. Nephro.l Dial. Transplant. 22, 2165-2174. (Pubitemid 47244693)
24. Phanish, M.K., Wahab, N.A., Hendry, B.M., Dockrell, M.E., 2005. TGF-beta1-induced connective tissue growth factor (CCN2) expression in human renal proximal tubule epithelial cells requires Ras/MEK/ERK and Smad signalling. Nephron. Exp. Nephrol. 100, e156-e165. (Pubitemid 40910994)
25. Remuzzi, G., Benigni, A., Remuzzi, A., 2006. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. Clin. Invest. 116, 288-296. (Pubitemid 43228342)
26. Rodriguez-Barbero, A., L'Azou, B., Cambar, J., Lopez-Novoa, J.M., 2000. Porential use of isolated glomeruli and cultured mesangial cells as in vitro models to assess nephropathy. Cell Biol. Toxicol. 16, 145-153.
27. Sato, T., Iwaki, M., Shimoqaito, N., Wu, X., Yanaqishi, S., Takeuchi, M., 2006. TAGE (toxic AGEs) theory in diabetic complications. Curr. Mol. Med. 6, 351-358.
28. Sharma, K., Ziyadeh, F.N., Alzahabi, B., McGowan, T.A., Kapoor, S., Kurnik, B.R., Kurnik, P.B., Weisberg, L.S., 1997. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 46, 854-859. (Pubitemid 27188264)
29. Sourris, K.C., Forbes, J.M., 2009. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy-are these receptors valid therapeutic targets. Curr. Drug Targets 10, 42-50.
30. Tan, A.l., Forbes, J.M., Cooper, M.E., 2007. AGE, RAGE and ROS in diabetic nephropathy. Semin. Nephrol. 27, 130-143. (Pubitemid 46550311)
31. Thomas, M.C., Fordes, J.M., Cooper, M.E., 2005. Advanced glycation end products and diabetic nephropathy. Am. J. Ther. 12, 562-572. (Pubitemid 41689757)
32. Thornalley, P.J., 2003. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch. Biochem. Biophys. 419, 31-40. (Pubitemid 37279141)
33. Thrailkill, K.M., Bunn, R.C., Fowlkes, J.L., 2009. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine 35, 1-10.
34. Valencia, J.V., Weldon, S.C., Quinn, D., Kiers, G.H., DeGroot, J., TeKoppele, J.M., Hughes, T.E., 2004. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal. Biochem. 324, 68-78. (Pubitemid 37491125)
35. Vinson, J.A., Howard, T.B., 1996. Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other vitamins and nutrients. J. Nutri. Biochem. 7, 659-663. (Pubitemid 27019421)
36. Voziyan, P.A., Hudson, B.G., 2005. Pyridoxamine: the many virtues of a maillard reaction inhibitor. Ann. N. Y. Acad. Sci. 1043, 807-816. (Pubitemid 41123975)
37. Wahab, N.A., Weston, B.S., Roberts, T., Mason, R.M., 2002. Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J. Am. Soc. Nephrol. 13, 2437-2445.
38. Wang, H., Li, H., Zuo, M., Zhang, Y., Liu, H., Fang, W., Chen, X., 2008. Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo. Cancer Lett. 268, 89-97.
39. Wendt, T.M., Tanji, N., Guo, J., Kislinger, T.R., Qu, W., Lu, Y., Bucciarelli, L.G., Rong, L.L., Moser, B., Markowitz, G.S., Stein, G., Bierhaus, A., Liliensiek, B., Arnold, B., Nawroth, P.P., Stern, D.M., D'Agati, V.D., Schmidt, A.M., 2003. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162, 1123-1137. (Pubitemid 36350658)
40. Wolf, G., 2000. Cell cycle regulation in diabetic nephropathy. Kidney Int. Suppl. 77, S59-S66.
41. Wolf, G., Ziyadeh, F.N., 1999. Molecular mechanism of diabetic renal hypertrophy. Kidney Int. 56, 393-405. (Pubitemid 29353136)
42. Youssef, S., Nguyen, D.T., Soulis, T., Pangiotopoulos, S., Jerums, G., Cooper, M.E., 1999. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. Kidney Int. 55, 907-916.
43. Zhou, G., Li, C., Cai, L., 2004. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. Am. J. Pathol. 6, 2033-2043. (Pubitemid 39578381)
44. Ziyadeh, F.N., 2004. Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J. Am. Soc. Nephrol. 15, S55-S57. (Pubitemid 38018457)